Phase 3Completed
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)
- Sponsor
- Pfizer (Industry)
- Enrollment
- 270 enrolled
- Conditions
- Ankylosing Spondylitis
- Interventions
- Tofacitinib
- Ages
- adults, older adults
- Registry
- NCT03502616, EUCTR2018-000226-58
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
Primary outcomes
- Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS)20 Response at Week 16
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered